Abstract
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:TNF as a Target of Inflammation in Rheumatoid Arthritis
Volume: 15 Issue: 2
Author(s): Hisashi Yamanaka
Affiliation:
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Abstract: Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Export Options
About this article
Cite this article as:
Yamanaka Hisashi, TNF as a Target of Inflammation in Rheumatoid Arthritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316121808
DOI https://dx.doi.org/10.2174/1871530315666150316121808 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Strategy of Virtual Screening based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis
Current Pharmaceutical Biotechnology Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major etabolitie, A77 1726
Drug Metabolism Letters α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology The Characteristic of Histopathology in Spondyloarthropathy
Current Rheumatology Reviews Central Nervous System-Related
Current Bioactive Compounds Sonoanatomy and Sonopathology of Complex Anatomic Areas
Current Rheumatology Reviews Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Current Rheumatology Reviews <sup>89</sup>Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals
Current Topics in Medicinal Chemistry Preface
Current Rheumatology Reviews Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Editorial [Hot topic: Thrombospondins (Guest Editor: Jack Lawler)]
Current Drug Targets Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Nanotechnology and Diabetic Wound Healing: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets